<DOC>
	<DOC>NCT01479764</DOC>
	<brief_summary>This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neuromuscular blockade with usual care (neostigmine/glycopyrrolate).</brief_summary>
	<brief_title>Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)</brief_title>
	<detailed_description />
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>American Society of Anesthesiologists (ASA) Class 1 or 2 or 3 Scheduled to undergo an elective abdominal surgical procedure under general anesthesia; and: expected to undergo neuromuscular relaxation with rocuronium for endotracheal intubation; and expected to require at least one maintenance dose of rocuronium; and expected to require active reversal of neuromuscular blockade; and expected to require clinical or subjective neuromuscular monitoring only; and expected to recover in the PACU Arm that is accessible for measuring the TOF ratio in the PACU Sexually active female patient of childbearing potential must agree to use a medically accepted method of contraception through seven days after receiving protocolspecified medication. Anatomical malformations that may lead to difficult intubation Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial assessments Dialysisdependent or has or is suspected of having severe renal insufficiency Significant hepatic dysfunction Family history of malignant hyperthermia Cardiac pacemaker Allergy to study treatments or its/their excipients, to opioids / opiates, sugammadex, muscle relaxants or their excipients, or other medication(s) used during general anesthesia Toremifene before or within 24 hours of study drug administration Scheduled for an overnight stay (or &gt;12 hours) in PACU Expected transfer to an Intensive Care Unit after surgery Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy followup visit Breastfeeding. Investigational drug(s) within 30 days of randomization on this study Participation in any other clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial Participant or family member is among the personnel of the investigational or Sponsor staff directly involved with this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>